“Many studies have demonstrated that the endocannabinoid system (ECS) is altered in different tumor types, including colon cancer.
However, little is known about the role of the ECS in tumor progression.
Here we report the correlation between CB 2 expression and pathological data in a series of 175 colorectal cancer patients, as well as the response of the HT29 colon cancer-derived cell line upon CB 2 activation…
These results raise the question whether the activation of CB 2 should be considered as anti-tumoral therapy.”